Suzhou Hemaijia Pharmaceutical

Suzhou Hemaijia Pharmaceutical is a clinical-stage biotechnology company based in Suzhou, China, dedicated to the discovery and development of innovative small molecule drugs. Founded in 2018, the company focuses on addressing significant unmet medical needs in the fields of immunology and oncology. Its lead candidate, HMJ-005, is a highly selective Tyrosine kinase 2 (TYK2) inhibitor currently in Phase 2 clinical trials for the treatment of psoriasis. Hemaijia leverages its internal research capabilities to develop a pipeline of high-selectivity inhibitors with the goal of providing safer and more effective therapeutic options. The company is situated in the BioBAY industrial cluster and is backed by regional venture capital firms.